DURECT Corporation (NASDAQ:DRRX)‘s stock had its “hold” rating restated by research analysts at HC Wainwright in a research note issued on Thursday.
A number of other equities analysts have also issued reports on DRRX. Stifel Nicolaus raised shares of DURECT Corporation from a “hold” rating to a “buy” rating and boosted their target price for the stock from $1.25 to $3.00 in a research report on Wednesday, July 12th. ValuEngine raised shares of DURECT Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. Finally, Laidlaw dropped their target price on shares of DURECT Corporation from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, October 20th.
DURECT Corporation (NASDAQ:DRRX) last announced its earnings results on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.10. DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%.
WARNING: “DURECT Corporation (DRRX) Given “Hold” Rating at HC Wainwright” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://sportsperspectives.com/2017/11/02/durect-corporation-drrx-given-hold-rating-at-hc-wainwright.html.
Institutional investors and hedge funds have recently bought and sold shares of the business. Voya Investment Management LLC boosted its stake in DURECT Corporation by 22.8% during the second quarter. Voya Investment Management LLC now owns 82,826 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 15,394 shares in the last quarter. SG Americas Securities LLC acquired a new stake in DURECT Corporation during the first quarter worth $147,000. State of Wisconsin Investment Board acquired a new stake in DURECT Corporation during the second quarter worth $151,000. The Manufacturers Life Insurance Company boosted its stake in DURECT Corporation by 12.1% during the second quarter. The Manufacturers Life Insurance Company now owns 120,977 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 13,072 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in DURECT Corporation by 12.0% during the second quarter. Rhumbline Advisers now owns 175,604 shares of the specialty pharmaceutical company’s stock worth $274,000 after buying an additional 18,871 shares in the last quarter. Hedge funds and other institutional investors own 45.91% of the company’s stock.
DURECT Corporation Company Profile
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.